NDA 219843 · Rosemont Pharms
Atmeksi
Methocarbamol · Oral · Muscle Relaxant
Last checked: Nov 20, 2026Latest source record: Jul 30, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Jul 30, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
33
8 Phase 3, 2 recruiting
FAERS reports
17,199
10,693 serious, 1,418 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 13, 2026.
ATMEKSI (methocarbamol) oral suspension is a muscle relaxant indicated as: an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions in patients 16 and older. 1.1 Acute, painful musculoskeletal conditions. ATMEKSI is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions in patients 16 and older. 1.1 Acute, painful musculoskeletal conditions. ATMEKSI is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions in patients 16 and older.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- ATMEKSI · METHOCARBAMOL 750MG/5ML · SUSPENSION, ORAL · Prescription
- ATMEKSI · METHOCARBAMOL 750MG(5ML) · SUSPENSION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Methocarbamol" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of Relaxin for the Treatment of Acute Heart FailurePivotal-lookingCompleted
Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companiesIndustry
NCT00520806 · 1,161 participants · Start Oct 2007 · Primary completion Sep 2012
Drug: Relaxin; Placebo · For: Heart Failure, Congestive
Sites: Chicago, Illinois; Detroit, Michigan; Safed, Israel
- An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain ServicePivotal-lookingNot yet recruiting
University of California, San FranciscoAcademic, hospital or other
NCT07296770 · 474 participants (planned) · Start Oct 1, 2026 · Primary completion Dec 1, 2028
Drug: Pharmacologic Pain Management · For: Postsurgical Pain Management; Postsurgical Pain, Chronic; Opioid Use After Surgery
Sites: San Francisco, California
- Study of the Relaxin Agonist R2R01 in Patients at High Risk for Cardiac Surgery Associated- Acute Kidney InjuryPivotal-lookingRecruiting
River 2 Renal Corp.Industry
NCT07625553 · 430 participants (planned) · Start Apr 7, 2026 · Primary completion Apr 1, 2027
Drug: R2R01 · For: Acute Kidney Injury
Sites: Milan, Italy
- A Phase IIb Study of AZD5462 in Patients With Chronic Heart FailurePivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT06299826 · 375 participants · Start Jun 4, 2024 · Primary completion Feb 10, 2026
Drug: AZD5462; Placebo · For: Chronic Heart Failure
Sites: Alexander City, Alabama; Northridge, California; Torrance, California · 57 sites in all
- Examining Analgesic Synergy and Efficacy in Trauma CarePivotal-lookingNot yet recruiting
Wake Forest University Health SciencesAcademic, hospital or other
NCT07435077 · 282 participants (planned) · Start Mar 2027 · Primary completion Jul 2027
Drug: Buprenorphine; Oxycodone · For: Opioid Use Disorder
Sites: Winston-Salem, North Carolina
- Orphenadrine and Methocarbamol for LBPPivotal-lookingCompleted
Montefiore Medical CenterAcademic, hospital or other
NCT02665286 · 240 participants · Start Mar 2016 · Primary completion Apr 2017
Drug: Orphenadrine; Methocarbamol and 2 more · For: Low Back Pain
Sites: The Bronx, New York
- Recombinant Human Relaxin in the Treatment of Diffuse SclerodermaPivotal-lookingCompleted
University of Medicine and Dentistry of New JerseyAcademic, hospital or other
NCT00704665 · 231 participants · Start Dec 1998 · Primary completion Dec 2001
Drug: Relaxin; Relaxin · For: Systemic Sclerosis
- Relaxin Therapy for Atrial FibrillationPivotal-lookingNot yet recruiting
Deeptankar DeMazumderFederal agency
NCT07359872 · 208 participants (planned) · Start Jan 1, 2027 · Primary completion Dec 31, 2030
Drug: Relaxin; Placebo · For: Atrial Fibrillation (AF); Arrhythmia; Oxidative Stress and 5 more
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue1,273
- pain1,245
- nausea1,191
- drug ineffective1,140
- headache973
- diarrhoea882
- off label use837
- fall813
- dyspnoea788
- arthralgia766
- dizziness696
- back pain652
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 108 |
| 2005 | 134 |
| 2006 | 131 |
| 2007 | 84 |
| 2008 | 134 |
| 2009 | 176 |
| 2010 | 199 |
| 2011 | 253 |
| 2012 | 349 |
| 2013 | 346 |
| 2014 | 378 |
| 2015 | 695 |
| 2016 | 972 |
| 2017 | 845 |
| 2018 | 1,084 |
| 2019 | 1,240 |
| 2020 | 1,353 |
| 2021 | 1,120 |
| 2022 | 1,214 |
| 2023 | 1,273 |
| 2024 | 1,485 |
| 2025 | 1,975 |
| 2026 | 1,651 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review.
Chou R, Peterson K, Helfand M · J Pain Symptom Manage 2004 · Comparative Study, Evaluation Study
- Does methocarbamol affect fatigue markers in the low-back electromyogram?
Boakes J, Peach JP, McGill SM · J Electromyogr Kinesiol 1998 · Clinical Trial, Comparative Study
- Randomized-controlled trial of methocarbamol as a novel treatment for muscle cramps in cirrhotic patients.
Abd-Elsalam S, Arafa M, Elkadeem M, et al. · Eur J Gastroenterol Hepatol 2019 · Randomized Controlled Trial
- Muscle relaxants for pain management in rheumatoid arthritis.
Richards BL, Whittle SL, Buchbinder R · Cochrane Database Syst Rev 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
- [Methocarbamol: central building block in multimodal therapy].
· MMW Fortschr Med 2016 · Randomized Controlled Trial
- Efficacy and safety of sodium hyaluronate in the treatment of Wilkes stage II disease.
Oliveras-Moreno JM, Hernandez-Pacheco E, Oliveras-Quintana T, et al. · J Oral Maxillofac Surg 2008 · Randomized Controlled Trial
Sponsor: Rosemont Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.